Partnering Trend With Big Pharma And Indian Companies On The Rise In Race For Discovery
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Chemical expertise, emerging R&D work and growing awareness of intellectual property rights are propelling foreign companies to seek collaborative agreements with Indian firms to develop new chemical entities, according to analysts
You may also be interested in...
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
NEW DELHI - The research unit of Indian firm Nicholas Piramal signed its second development deal with Eli Lilly Feb. 15, worth up to $110 million, to carry out clinical work on two unspecified drugs "directed against the same target" and participate in further studies, manufacturing and sales
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).